Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Rhea-AI Summary

Ventyx Biosciences (Nasdaq: VTYX), a clinical-stage biopharmaceutical company, will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on March 30, 2023, from 2:00-2:30 PM ET. The event, focused on innovative oral therapies for inflammatory diseases, will be accessible via webcast on the company’s website, with a replay available for thirty days post-event. Ventyx aims to address significant unmet needs in autoimmune disorders with its pipeline targeting TYK2, S1P1R, and NLRP3, potentially revolutionizing treatment options.

ENCINITAS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference being held on March 30, 2023.

• Event: H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
  Location: Virtual
  Date: Thursday, March 30, 2023
  Time: 2:00-2:30 PM ET

A webcast of the presentation will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of the event for thirty days.

About Ventyx Biosciences

Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift immunology markets from injectable to oral drugs. Our current pipeline includes three internally discovered clinical programs targeting TYK2, S1P1R and NLRP3, positioning us to become a leader in the development of oral immunology therapies. Ventyx is headquartered in Encinitas, California. For more information about Ventyx, please visit www.ventyxbio.com.

Investor Relations Contact
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
IR@ventyxbio.com

FAQ

What is the date and time of Ventyx Biosciences' presentation at the conference?

Ventyx Biosciences will present on March 30, 2023, from 2:00 to 2:30 PM ET.

Where can I watch the Ventyx Biosciences presentation?

The presentation can be watched via webcast on the Ventyx website.

What is the focus of Ventyx Biosciences?

Ventyx Biosciences focuses on developing novel oral therapies for autoimmune and inflammatory diseases.

What are the key programs in Ventyx's pipeline?

Ventyx's pipeline includes programs targeting TYK2, S1P1R, and NLRP3.

How long will the webcast replay of the Ventyx Biosciences event be available?

The webcast replay will be available for thirty days after the event.